scholarly article | Q13442814 |
P2093 | author name string | Danuta Duś | |
Marek Bębenek | |||
Joanna Koźlak | |||
P2860 | cites work | The Fas death factor | Q29620461 |
Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege | Q33997713 | ||
The prognostic molecular markers in hepatocellular carcinoma | Q34668320 | ||
Messengers of cell death: apoptotic signaling in health and disease. | Q35072921 | ||
Death receptor-induced cell killing | Q35592675 | ||
Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease | Q35597411 | ||
Expression of Fas ligand in liver metastases of human colonic adenocarcinomas | Q36186304 | ||
Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression | Q36615251 | ||
Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells | Q36621610 | ||
Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand | Q40651320 | ||
Fas expression and function in normal and malignant breast cell lines. | Q41158790 | ||
FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas | Q42020999 | ||
Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium | Q42808304 | ||
The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. | Q43918657 | ||
Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy | Q44772620 | ||
Diagnostic and prognostic value of fas and telomeric-repeat binding factor-1 genes in adrenal tumors | Q46052425 | ||
Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma. | Q47617874 | ||
Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread. | Q51762374 | ||
Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy. | Q51987890 | ||
Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. | Q53962194 | ||
Mechanisms of apoptosis | Q56609201 | ||
Prognostic relevance of altered Fas (CD95)-system in human breast cancer | Q61900217 | ||
Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand | Q64378160 | ||
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape | Q71762882 | ||
Time dependency of the influence of prognostic factors on relapse in breast cancer | Q72559248 | ||
Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast | Q72999905 | ||
Circulating soluble Fas concentration in breast cancer patients | Q73253501 | ||
FasL:Fas ratio--a prognostic factor in breast carcinomas | Q73519176 | ||
Fas and Fas ligand as prognostic factors in human breast carcinoma | Q79314094 | ||
Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer | Q81677197 | ||
P433 | issue | 2 | |
P304 | page(s) | 120-122 | |
P577 | publication date | 2013-04-29 | |
P1433 | published in | Contemporary oncology | Q27717613 |
P1476 | title | Prognostic value of the Fas/Fas ligand system in breast cancer | |
P478 | volume | 17 |
Q33793046 | HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model |
Q37712385 | Mechanism of immune evasion in breast cancer |
Q94503525 | The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis |
Q92511522 | Weighted Fused Pathway Graphical Lasso for Joint Estimation of Multiple Gene Networks |
Search more.